Capital International Investors trimmed its position in GSK plc (NYSE:GSK – Get Rating) by 0.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,100,242 shares of the pharmaceutical company’s stock after selling 17,984 shares during the period. Capital International Investors owned approximately 0.75% of GSK worth $832,007,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. KG&L Capital Management LLC lifted its holdings in GSK by 0.8% in the first quarter. KG&L Capital Management LLC now owns 29,611 shares of the pharmaceutical company’s stock valued at $1,290,000 after acquiring an additional 225 shares during the period. Koss Olinger Consulting LLC lifted its holdings in GSK by 3.4% in the first quarter. Koss Olinger Consulting LLC now owns 7,299 shares of the pharmaceutical company’s stock valued at $318,000 after acquiring an additional 242 shares during the period. Steel Peak Wealth Management LLC lifted its holdings in GSK by 4.6% in the first quarter. Steel Peak Wealth Management LLC now owns 5,543 shares of the pharmaceutical company’s stock valued at $241,000 after acquiring an additional 246 shares during the period. Tsfg LLC lifted its holdings in GSK by 67.9% in the first quarter. Tsfg LLC now owns 618 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 250 shares during the period. Finally, Glassman Wealth Services lifted its holdings in GSK by 71.3% in the fourth quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company’s stock valued at $28,000 after acquiring an additional 261 shares during the period. 16.86% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on GSK shares. AlphaValue downgraded GSK to a “reduce” rating in a report on Tuesday, July 19th. Credit Suisse Group raised their target price on GSK from GBX 1,400 ($16.92) to GBX 1,600 ($19.33) in a report on Friday, July 15th. Deutsche Bank Aktiengesellschaft cut their price target on GSK from GBX 1,750 ($21.15) to GBX 1,500 ($18.12) in a research note on Wednesday, September 7th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating in a research note on Thursday, September 8th. Finally, Morgan Stanley cut their price target on GSK from GBX 1,860 ($22.47) to GBX 1,550 ($18.73) in a research note on Wednesday, September 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $1,700.00.
GSK Trading Down 1.4 %
GSK Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 6th. Investors of record on Friday, August 19th will be paid a $0.383 dividend. This is an increase from GSK’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, August 18th. This represents a $1.53 annualized dividend and a yield of 4.91%. GSK’s payout ratio is presently 50.66%.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.